Dispatch Biotherapeutics

Biotech

dispatchbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
24
0 granted · 24 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2003FORMATION VENTURE ENGINEERING FOUNDRY INC——
2004Converge Bio Inc.—$25M
2005ALPHA YOUNG LLC——
2006Dispatch Biotherapeutics——
2007OROX BIOSCIENCES, INC.——
2008cAMPfield Therapeutics——
2009Neuron23——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 24
  • Systems And Methods For Expression Of Synthetic Cancer Antigens And Cytokine Receptorsapplication
  • Viral Vectors For Expression Of Synthetic Cancer Antigens And Chemokine And Related Methods And Usesapplication
  • Systems And Methods For Expression Of Synthetic Cancer Antigens And Cytokine Receptorsapplication
  • Systems And Methods For Expression Of Synthetic Cancer Antigens And Cytokine Receptorsapplication
  • Systems And Methods For Expression Of Synthetic Cancer Antigens And Cytokine Receptorsapplication
  • Tethered IL-9/IL-9R And Related Engineered Cells And Methodsapplication
  • Modified Lentiviral Transfer Plasmidsapplication
  • Engineered Cancer Antigens And Related Methods And Usesapplication
  • Engineered Cancer Antigens With Modified Domains And Related Methods And Usesapplication
  • Tethered IL-9/IL-9R And Related Engineered Cells And Methodsapplication
  • Engineered Cancer Antigens With Modified Domains And Related Methods And Usesapplication
  • Engineered Cancer Antigens And Related Methods And Usesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.